Wednesday, June 10, 2026

Patent intelligence · CA

CA 3174918

OPICAPONE MICRONISEE

granted A61K 9/ 16 A IA61K 9/ 20 A IA61K 31/ 4439 A IA61K/314439
Status granted
Linked drugs 1
Pipeline programs 5
Years to expiry 15
Applicant portfolio 25
Patent details — CA 3174918
Jurisdiction
CA
Status
granted
Grant date
Sep 16, 2021
Expiration
Sep 11, 2041
CPC classes
A61K 9/ 16 A I, A61K 9/ 20 A I, A61K 31/ 4439 A I, A61K/314439
View on Google Patents ↗

Quick answer

CA 3174918 (OPICAPONE MICRONISEE) is held by BIAL PORTELA & CA SA [PT]. Status: granted. Granted Sep 16, 2021. Expires Sep 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 9/ 16 A I, A61K 9/ 20 A I, A61K 31/ 4439 A I, A61K/314439, A61K/916, A61K/91688

More from BIAL PORTELA & CA SA [PT]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026106499

    ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES

    BIAL PORTELA & CA SA [PT] · Expires May 16, 2046

    granted
  2. WO 2026015039

    THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1

    BIAL PORTELA & CA SA [PT] · Expires Jan 10, 2046

    granted
  3. WO 2025211975

    AGONISTES DU RÉCEPTEUR DE L'OREXINE

    BIAL PORTELA & CA SA [PT] · Expires Oct 4, 2045

    granted
  4. WO 2025023852

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Expires Jan 25, 2045

    granted
  5. WO 2025023851

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Expires Jan 25, 2045

    granted
  6. WO 2024242579

    RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE

    BIAL PORTELA & CA SA [PT] · Expires Nov 23, 2044

    granted
  7. AU 2023244944

    PRODRUGS OF OPICAPONE

    BIAL PORTELA & CA SA [PT] · Expires Sep 28, 2044

    granted
  8. WO 2024039256

    RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON

    BIAL PORTELA & CA SA [PT] · Expires Feb 17, 2044

    granted

Frequently asked questions

What is US patent 3174918?

CA 3174918 (OPICAPONE MICRONISEE) is held by BIAL PORTELA & CA SA [PT]. Status: granted. Granted Sep 16, 2021. Expires Sep 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns CA 3174918?

BIAL PORTELA & CA SA [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does CA 3174918 expire?

Our index shows an expiration date of Sep 11, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.